问题 › 毛利率正在收窄 › HealthTech与数字健康
毛利率很少因为PMPM成本上升而下降。它下降是因为风险分担比例增加，而合同条款没有重新定价。 数字健康公司面临一个具体困境：承担结果风险的速度，超过了公司判断自己能否承担的速度——12个月测量窗口对11个月销售周期。在定价前，风险分担收入比例会因无人能归因的原因持续变动，产品毛利率的争论仍只是意见。
毛利率很少因为PMPM成本上升而下降。它下降是因为风险分担比例增加，而合同条款没有重新定价。 数字健康公司面临一个具体困境：承担结果风险的速度，超过了公司判断自己能否承担的速度——12个月测量窗口对11个月销售周期。在定价前，风险分担收入比例会因无人能归因的原因持续变动，产品毛利率的争论仍只是意见。
毛利率收窄有三个可能原因，需要相反的应对。风险分担比例上升而PMPM未跟上。合同组合转向参与率较低、归因结果较差的合同。或者交付结果的成本在无形中上升——更多干预、更多触达、更多返工——而人群条款未变。
第三种最常见也最难发现，因为它从未表现为成本增加。它表现为同样的收入需要公司投入更多资源才能达到合同结果。混合毛利率完全掩盖它：45%和15%的合同平均后仍是体面的30%。
因此第一步几乎从来不是成本削减计划，而是把毛利率按合同、按人群细分、按渠道拆开，直到平均值不再误导。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ ARR上升而毛利率持平或下降
✓ 整体毛利率看似可接受，却没人能说出具体风险分担合同的毛利率
✓ 风险分担比例让步在季度末已成为常规
通常会让情况更糟的做法。 推行全公司范围的成本削减，这会最重打击仍能产生正毛利的合同，因为交付能力正集中在那里。
It is for you if you run or finance a digital health company and revenue is up and profit is not. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 成本与毛利率改善, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
先提价，如果分析显示实际价格已低于交付价值——它出现在下一张发票上，无需新客户。先降成本，如果问题是服务成本而非价格。同时做两者就无法判断哪一个起了作用。
不需要。取十个最大客户，分配明显的可变投入——支持小时数、交付例外、定制工作、付款条款。排名几乎总是在数字精确前就已清晰，而排名就是决策。
不是。故意用毛利率换份额是一种策略。问题是未决定就滑入其中，而这几乎总是发生，因为每个单独折扣都有理由，模式直到年底才可见。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית